碳酸氢钠补充对非酸中毒性糖尿病肾病患者尿TGF-β1的影响:随机对照试验
本研究为随机双盲安慰剂对照试验,纳入74例血清总CO2正常的糖尿病肾病患者,口服碳酸氢钠或安慰剂6个月。结果显示碳酸氢钠未显著降低尿TGF-β1/肌酐、KIM-1、纤连蛋白、NGAL或UACR。
要点
- 在非酸中毒性糖尿病肾病中,碳酸氢钠未显著减少尿TGF-β1等纤维化或损伤标志物。
- 碳酸氢钠可升高血清总CO2和尿pH,降低尿铵和可滴定酸排泄。
- 该人群6个月碳酸氢钠治疗对尿白蛋白排泄无显著影响。
核心结论
- 在非酸中毒性糖尿病肾病中,口服碳酸氢钠6个月未显著降低尿TGF-β1、KIM-1、纤连蛋白、NGAL或UACR。
研究设计与样本
- 随机双盲安慰剂对照研究,纳入74例美国退伍军人,患有1型或2型糖尿病,eGFR 15-89 ml/min/1.73 m2,UACR≥30 mg/g,血清总CO2 22-28 meq/L。
- 参与者接受口服碳酸氢钠(0.5 meq/kg瘦体重/天;n=35)或安慰剂(n=39)治疗6个月。
- 主要结局为基线至第3个月和第6个月尿TGF-β1/肌酐的变化。
主要发现
- 碳酸氢钠组平均总CO2升高1.2(95% CI 0.3至2.1)meq/L,尿pH升高0.6(95% CI 0.5至0.8)。
- 碳酸氢钠组尿铵排泄减少5(95% CI 0至11)meq/d,尿可滴定酸排泄减少11(95% CI 5至18)meq/d。
- 尿TGF-β1/肌酐组间变化差异为13%(95% CI -10%至40%),无统计学意义。
- KIM-1/肌酐组间变化差异为-10%(95% CI -38%至31%),纤连蛋白/肌酐为8%(95% CI -15%至37%),NGAL/肌酐为-33%(95% CI -56%至4%),UACR为1%(95% CI -25%至36%),均无显著差异。
临床怎么用
- 对于血清总CO2正常的糖尿病肾病患者,碳酸氢钠补充可能不能减少肾脏纤维化或损伤标志物。
- 临床决策应基于其他循证适应症,而非期望通过碳酸氢钠降低这些生物标志物。
局限性
- 样本量较小(74例),研究人群为美国退伍军人,以老年男性为主,结果外推需谨慎。
- 研究期限为6个月,长期效应未知。
- 主要结局为替代标志物,未评估硬终点如eGFR下降或终末期肾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In early-phase studies of individuals with hypertensive CKD and normal serum total CO2, sodium bicarbonate reduced urinary TGF-β1 levels and preserved kidney function. The effect of sodium bicarbonate on kidney fibrosis and injury markers in individuals with diabetic kidney disease and normal serum total CO2 is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a randomized, double-blinded, placebo-controlled study in 74 United States veterans with type 1 or 2 diabetes mellitus, eGFR of 15-89 ml/min per 1.73 m2, urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g, and serum total CO2 of 22-28 meq/L. Participants received oral sodium bicarbonate (0.5 meq/kg lean body wt per day; n=35) or placebo (n=39) for 6 months. The primary outcome was change in urinary TGF-β1-to-creatinine from baseline to months 3 and 6. Secondary outcomes included changes in urinary kidney injury molecule-1 (KIM-1)-to-creatinine, fibronectin-to-creatinine, neutrophil gelatinase-associated lipocalin (NGAL)-to-creatinine, and UACR from baseline to months 3 and 6. RESULTS: Key baseline characteristics were age 72±8 years, eGFR of 51±18 ml/min per 1.73 m2, and serum total CO2 of 24±2 meq/L. Sodium bicarbonate treatment increased mean total CO2 by 1.2 (95% confidence interval [95% CI], 0.3 to 2.1) meq/L, increased urinary pH by 0.6 (95% CI, 0.5 to 0.8), and decreased urinary ammonium excretion by 5 (95% CI, 0 to 11) meq/d and urinary titratable acid excretion by 11 (95% CI, 5 to 18) meq/d. Sodium bicarbonate did not significantly change urinary TGF-β1/creatinine (difference in change, 13%, 95% CI, -10% to 40%; change within the sodium bicarbonate group, 8%, 95% CI, -10% to 28%; change within the placebo group, -4%, 95% CI, -19% to 13%). Similarly, no significant effect on KIM-1-to-creatinine (difference in change, -10%, 95% CI, -38% to 31%), fibronectin-to-creatinine (8%, 95% CI, -15% to 37%), NGAL-to-creatinine (-33%, 95% CI, -56% to 4%), or UACR (1%, 95% CI, -25% to 36%) was observed. CONCLUSIONS: In nonacidotic diabetic kidney disease, sodium bicarbonate did not significantly reduce urinary TGF-β1, KIM-1, fibronectin, NGAL, or UACR over 6 months.
引用
- Raphael KL, Greene T, Wei G, et al. Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. Clin J Am Soc Nephrol. 2020. PMID: 31974286. doi:10.2215/CJN.06600619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。